Abstract
Background: Intracerebral hemorrhage (ICH) is the most lethal subtype of stroke, a leading cause of death and disability in developed countries. Therapeutic options are notably limited. There is no specific pharmacological treatment, and early surgery has few indications that represent only a small clinically relevant survival advantage. It is therefore mandatory to investigate repairing processes after ICH in order to develop related therapeutic strategies.
Methods: The goal of this review is to discuss the current status of knowledge about the potential therapeutic role of endothelial progenitor cells (EPCs) in ICH, as well as the possible molecular mechanisms and future perspectives. Results: ICH is characterized by a primary vascular rupture, followed by a secondary vascular tearing due to the peripheral pressure exerted by the hematoma. Hypoperfusion may also play a role, although not as markedly as in ischemic stroke. In this context, the repairing of damaged vessels and the development of new ones seem logical therapeutic targets. Circulating EPCs have been suggested to play a major role in re-endothelization, angiogenesis and vasculogenesis. Congruently, EPC levels have been associated with good neurological and functional outcome as well as with reduced residual volume in patients with acute ICH. Conclusion: An EPC-based therapy, acting primarily through angiogenic mechanisms, may be a valid therapeutic option in ICH.Keywords: Angiogenesis, cellular therapy, endothelial progenitor cells, intracerebral hemorrhage, outcome, vasculogenesis.
Current Pharmaceutical Design
Title:Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Volume: 23 Issue: 15
Author(s): Juan Pías-Peleteiro, Francisco Campos, María Perez-Mato, Esteban Lopez-Arias, Manuel Rodriguez-Yanez, Jose Castillo*Tomas Sobrino*
Affiliation:
- Clinical Neurosciences Research Laboratory, Department of Neurology, Hospital Clínico Universitario, Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela,Spain
- Department of Neurology, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitário, Travesa da Choupana S/N, 15706 - Santiago de Compostela,Spain
Keywords: Angiogenesis, cellular therapy, endothelial progenitor cells, intracerebral hemorrhage, outcome, vasculogenesis.
Abstract: Background: Intracerebral hemorrhage (ICH) is the most lethal subtype of stroke, a leading cause of death and disability in developed countries. Therapeutic options are notably limited. There is no specific pharmacological treatment, and early surgery has few indications that represent only a small clinically relevant survival advantage. It is therefore mandatory to investigate repairing processes after ICH in order to develop related therapeutic strategies.
Methods: The goal of this review is to discuss the current status of knowledge about the potential therapeutic role of endothelial progenitor cells (EPCs) in ICH, as well as the possible molecular mechanisms and future perspectives. Results: ICH is characterized by a primary vascular rupture, followed by a secondary vascular tearing due to the peripheral pressure exerted by the hematoma. Hypoperfusion may also play a role, although not as markedly as in ischemic stroke. In this context, the repairing of damaged vessels and the development of new ones seem logical therapeutic targets. Circulating EPCs have been suggested to play a major role in re-endothelization, angiogenesis and vasculogenesis. Congruently, EPC levels have been associated with good neurological and functional outcome as well as with reduced residual volume in patients with acute ICH. Conclusion: An EPC-based therapy, acting primarily through angiogenic mechanisms, may be a valid therapeutic option in ICH.Export Options
About this article
Cite this article as:
Pías-Peleteiro Juan, Campos Francisco, Perez-Mato María, Lopez-Arias Esteban, Rodriguez-Yanez Manuel, Castillo Jose*, Sobrino Tomas*, Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage, Current Pharmaceutical Design 2017; 23 (15) . https://dx.doi.org/10.2174/1381612822666161221153937
DOI https://dx.doi.org/10.2174/1381612822666161221153937 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells and Nanoparticles in Therapy
Nanoscience & Nanotechnology-Asia Therapeutic Angiogenesis by Gene Transfer in Critical Limb and Myocardial Ischemia
Current Pharmaceutical Design Optical Techniques in the Assessment of Peripheral Arterial Disease
Current Vascular Pharmacology Small Molecular Weight Inhibitors of Stress-Activated and Mitogen- Activated Protein Kinases
Mini-Reviews in Medicinal Chemistry Potential Applications of Induced Pluripotent Stem Cells for Cardiovascular Diseases
Current Drug Targets Molecular Dissection of Renal Ischemia-Reperfusion: Oxidative Stress and Cellular Events
Current Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation
Current Vascular Pharmacology Gas Bioengineering Using Hemoglobin-Vesicles For Versatile Clinical Applications
Current Pharmaceutical Design Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry Heme Oxygenase System and Hypertension: A Comprehensive Insight
Current Pharmaceutical Design Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design New Frontiers in the Management of Acute Coronary Syndromes: Cangrelor and Elinogrel
Recent Patents on Cardiovascular Drug Discovery Placental Hypoxia Developed During Preeclampsia Induces Telocytes Apoptosis in Chorionic Villi Affecting The Maternal-Fetus Metabolic Exchange
Current Stem Cell Research & Therapy The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design